In the fasted state, increases in circulating glucagon promote hepatic glucose production through induction of the gluconeogenic program. Triggering of the cyclic AMP pathway increases gluconeogenic gene expression via the de-phosphorylation of the CREB co-activator CRTC2 (ref. 1). Glucagon promotes CRTC2 dephosphorylation in part through the protein kinase A (PKA)-mediated inhibition of the CRTC2 kinase SIK2. A number of Ser/Thr phosphatases seem to be capable of dephosphorylating CRTC2 (refs 2, 3), but the mechanisms by which hormonal cues regulate these enzymes remain unclear. Here we show in mice that glucagon stimulates CRTC2 dephosphorylation in hepatocytes by mobilizing intracellular calcium stores and activating the calcium/calmodulin-dependent Ser/Thr-phosphatase calcineurin (also known as PP3CA). Glucagon increased cytosolic calcium concentration through the PKA-mediated phosphorylation of inositol-1,4,5-trisphosphate receptors (InsP 3 Rs), which associate with CRTC2. After their activation, InsP 3 Rs enhanced gluconeogenic gene expression by promoting the calcineurinmediated dephosphorylation of CRTC2. During feeding, increases in insulin signalling reduced CRTC2 activity via the AKT-mediated inactivation of InsP 3 Rs. InsP 3 R activity was increased in diabetes, leading to upregulation of the gluconeogenic program. As hepatic downregulation of InsP 3 Rs and calcineurin improved circulating glucose levels in insulin resistance, these results demonstrate how interactions between cAMP and calcium pathways at the level of the InsP 3 R modulate hepatic glucose production under fasting conditions and in diabetes.
In the fasted state, increases in circulating glucagon promote hepatic glucose production through induction of the gluconeogenic program. Triggering of the cyclic AMP pathway increases gluconeogenic gene expression via the de-phosphorylation of the CREB co-activator CRTC2 (ref. 1) . Glucagon promotes CRTC2 dephosphorylation in part through the protein kinase A (PKA)-mediated inhibition of the CRTC2 kinase SIK2. A number of Ser/Thr phosphatases seem to be capable of dephosphorylating CRTC2 (refs 2, 3), but the mechanisms by which hormonal cues regulate these enzymes remain unclear. Here we show in mice that glucagon stimulates CRTC2 dephosphorylation in hepatocytes by mobilizing intracellular calcium stores and activating the calcium/calmodulin-dependent Ser/Thr-phosphatase calcineurin (also known as PP3CA). Glucagon increased cytosolic calcium concentration through the PKA-mediated phosphorylation of inositol-1,4,5-trisphosphate receptors (InsP 3 Rs), which associate with CRTC2. After their activation, InsP 3 Rs enhanced gluconeogenic gene expression by promoting the calcineurinmediated dephosphorylation of CRTC2. During feeding, increases in insulin signalling reduced CRTC2 activity via the AKT-mediated inactivation of InsP 3 Rs. InsP 3 R activity was increased in diabetes, leading to upregulation of the gluconeogenic program. As hepatic downregulation of InsP 3 Rs and calcineurin improved circulating glucose levels in insulin resistance, these results demonstrate how interactions between cAMP and calcium pathways at the level of the InsP 3 R modulate hepatic glucose production under fasting conditions and in diabetes.
We tested a series of Ser/Thr protein phosphatase inhibitors for their ability to block CRTC2 activation in response to glucagon. Exposure to the calcineurin inhibitor cyclosporine A (CsA) disrupted the glucagon-induced dephosphorylation and nuclear translocation of CRTC2, but okadaic acid, an inhibitor of PP1, PP2A and PP4 did not ( Fig. 1a and Supplementary Fig. 1a ). CsA and other calcineurin inhibitors also reduced cAMP response element (CRE)-luciferase (Luc) reporter activity ( Fig. 1a and Supplementary Fig. 1b ), but they had no effect in cells expressing phosphorylation-defective (Ser 171, 275 Ala) and therefore active forms of CRTC2 ( Supplementary Fig. 1c-e) .
On the basis of the ability of CsA to interfere with CRTC2 activation, we considered that calcineurin may promote the dephosphorylation of CRTC2 in response to glucagon. Supporting this idea, CRTC2 contains two consensus (PXIXIT) motifs that mediate an association with calcineurin 3, 4 ( Supplementary Fig. 2a, b) . Moreover, mutation of both motifs disrupted the glucagon-dependent dephosphorylation of CRTC2 (Fig. 1b) and prevented its nuclear translocation ( Supplementary Fig.  2c ), thereby down-regulating CRE-Luc activation (Fig. 1b) .
On the basis of these results, we tested whether calcineurin modulates expression of the gluconeogenic program. Adenoviral overexpression of the calcineurin catalytic subunit in hepatocytes augmented CRTC2 dephosphorylation, CRE-Luc activity, and glucose secretion in response to glucagon, whereas calcineurin knockdown had the opposite effect (Fig. 1c) . Although calcineurin could, in principle, modulate CRTC2 activity indirectly through effects on cAMP signalling, calcineurin overexpression or knockdown did not alter the phosphorylation of cellular PKA substrates in cells exposed to glucagon ( Supplementary  Fig. 2d ).
We examined next whether calcineurin modulates hepatic gluconeogenesis in vivo. Modest (twofold) overexpression of calcineurin in liver increased gluconeogenic gene expression, hepatic CRE-Luc activity, and fasting blood glucose concentrations ( Fig. 1d and Supplementary  Fig. 3a) . Conversely, knockdown of hepatic calcineurin reduced expression of the gluconeogenic program and lowered circulating glucose levels ( Fig. 1d and Supplementary Fig. 3b ), demonstrating that this phosphatase contributes to fasting adaptation in the liver. Calcineurin seemed to stimulate gluconeogenesis via the CREB pathway; depletion of CRTC2 blocked the effects of calcineurin overexpression ( Supplementary Fig. 4 ).
Realizing that calcineurin activity is dependent on increases in intracellular calcium, we tested whether the cAMP pathway stimulates calcium mobilization. Exposure of primary hepatocytes to glucagon triggered a rapid increase in cellular free calcium ( Fig. 2a and Supplementary Fig. 5a ); these effects were partially reversed by cotreatment with the PKA inhibitor H89 (Supplementary Fig. 5b ). The rise in intracellular calcium seems to be critical for CRTC2 activation, because co-incubation with the calcium chelator BAPTA disrupted CRTC2 dephosphorylation and CRE-Luc activation in response to glucagon (Fig. 2b) . Arguing against an effect of calcium on cAMP signalling, exposure to BAPTA did not block the PKA-mediated phosphorylation of CREB in response to glucagon.
We imagined that cAMP may increase calcium mobilization through the PKA-dependent phosphorylation of an intracellular calcium channel. In mass spectrometry studies to identify proteins that undergo phosphorylation by PKA in response to glucagon, we recovered the inositol 1,4,5-trisphosphate receptor 1 (InsP 3 R1) from immunoprecipitates of phospho-PKA substrate antiserum (Supplementary Fig. 5c ). InsP 3 R1 and its related family members (InsP 3 R2, InsP 3 R3) are calcium release channels that promote the mobilization of endoplasmic reticulum calcium stores following their activation in response to extracellular signals [5] [6] [7] [8] [9] . Moreover, cAMP agonists have also been shown to enhance InsP 3 R receptor activity through PKA-mediated phosphorylation.
Inhibiting InsP 3 Rs, either by exposure of hepatocytes to xestospongin C or by knockdown of all three InsP 3 Rs, disrupted cytosolic calcium mobilization and calcineurin activation in response to glucagon and forskolin ( Fig. 2a and Supplementary Fig. 6a ). Moreover, xestospongin C treatment and InsP 3 R knockdown also blocked the effects of glucagon on CRTC2 dephosphorylation, CRE-Luc activation, and induction of the gluconeogenic program ( Fig. 2c and Supplementary Fig. 6a, b) . We 
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confirmed the effects of InsP 3 R depletion using hepatocytes from mice with a knockout of the InsP 3 R2 (ref. 10), the predominant InsP 3 R isoform in these cells ( Supplementary Fig. 6c-e) .
On the basis of these results, InsP 3 Rs would also be expected to modulate fasting glucose production in vivo. Decreasing hepatic InsP 3 R expression, either by knockdown of all three InsP 3 Rs in liver or by targeted disruption of the Insp3r2 gene, reduced fasting CRE-Luc activity, gluconeogenic gene expression, and circulating glucose concentrations, demonstrating the importance of these receptors in glucose homeostasis (Fig. 2d and Supplementary Fig. 7) .
We tested whether glucagon modulates InsP 3 R activity through PKA-mediated phosphorylation. Exposure of hepatocytes to glucagon increased the phosphorylation of InsP 3 R1 as well as InsP 3 R2 and InsP 3 R3 by immunoblot assay with phospho-PKA substrate antiserum; these effects were blocked by the PKA inhibitor H89 (Fig. 3a and Supplementary Fig. 8a ). Moreover, mutation of serine residues at consensus PKA sites in InsP 3 R1 (Ser 1589, Ser 1756) to alanine completely disrupted InsP 3 R1 phosphorylation in response to glucagon (Fig. 3b) . As a result, overexpression of PKA-defective (S1589,1756A) InsP 3 R1 interfered with calcium mobilization and calcineurin activation, and it reduced CRE-Luc activation and glucose secretion from hepatocytes exposed to glucagon (Fig. 3b-d) .
Similar to glucagon, fasting also stimulated hepatic InsP 3 R1 phosphorylation at Ser 1589 and Ser 1756 ( Supplementary Fig. 8b ). And overexpression of PKA-defective InsP 3 R1 reduced fasting CRE-Luc induction, calcineurin activation, and gluconeogenic gene expression, leading to lower circulating glucose concentrations (Fig. 3e and Supplementary Fig. 8c, d ). Taken together, these results support an important role for the PKA-mediated phosphorylation of InsP 3 R in hepatic gluconeogenesis.
We considered that the proximity of CRTC2 to the calcium signalling machinery may be important for its activation. Supporting this notion, CRTC2 was found to associate with InsP 3 R1 via its aminoterminal CREB binding domain (CBD) in co-immunoprecipitation assays ( Fig. 3f and Supplementary Fig. 9a-d) . Moreover, CRTC2 was enriched in endoplasmic reticulum containing high density microsomal fractions, which also contain the InsP 3 Rs ( Supplementary  Fig. 9e ). The InsP 3 R-CRTC2 association seems to be critical for CRTC2 localization in the perinuclear space, because RNA interference (RNAi)-mediated knockdown of the InsP 3 Rs led to redistribution of CRTC2 in the cytoplasm (Supplementary Fig. 9f ). Disrupting the CRTC2-InsP 3 R interaction, by deletion of the CBD in CRTC2 or by addition of an N-terminal myristoylation signal that targets CRTC2 to the plasma membrane, blocked CRTC2 dephosphorylation and CREreporter activation in response to glucagon ( Supplementary Fig. 9g-i) . Taken together, these results suggest that the association of CRTC2 with InsP 3 Rs enhances its sensitivity to fasting signals.
Under feeding conditions, insulin inhibits gluconeogenesis in part by increasing CRTC2 phosphorylation. We wondered whether insulin interferes with InsP 3 R effects on CRTC2 activitation. Supporting this idea, AKT has been shown to block calcium mobilization by phosphorylating InsP 3 Rs at Ser 2682 (in InsP 3 R1) 11 . Indeed, exposure of hepatocytes to insulin increased InsP 3 R phosphorylation by immunoblot analysis with phospho-AKT substrate antiserum ( Supplementary  Fig. 10a ); mutation of Ser 2682 (in InsP 3 R1) to alanine blocked these effects. Insulin treatment also reduced glucagon-dependent increases in calcium mobilization and calcineurin activation in cells expressing wild-type InsP 3 R1, but it had no effect in cells expressing AKT-defective (S2682A) InsP 3 R1 (Supplementary Fig. 10b ). As a result, CRTC2 dephosphorylation, CRE-Luc activity, and glucose output were elevated in hepatocytes expressing InsP 3 R(S2682A) compared to wild type ( Supplementary Fig. 10c) .
We examined whether InsP 3 R1 phosphorylation by AKT is important in regulating hepatic glucose production in vivo. In line with this 
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notion, feeding increased hepatic InsP 3 R1 phosphorylation at Ser 2682 ( Supplementary Fig. 8b ). Moreover, overexpression of AKT-defective InsP 3 R1 partially suppressed feeding-induced decreases in CRE-Luc activity and gluconeogenic gene expression, leading to elevations in circulating glucose concentrations (Supplementary Fig. 10d ). Taken together, these results suggest that the AKT-mediated phosphorylation of InsP 3 Rs during feeding inhibits hepatic gluconeogenesis by blocking the calcineurin-dependent dephosphorylation of CRTC2.
We wondered whether hepatic InsP 3 R signalling contributes to increases in gluconeogenesis in the setting of insulin resistance. Supporting this notion, hepatic calcineurin activity was enhanced in both ob/ob and db/db diabetic animals, leading to increases in CRELuc activity (Fig. 4a and Supplementary Fig. 11a, b ). Pointing to a role for InsP 3 R, hepatic amounts of PKA-phosphorylated, active InsP 3 Rs were increased in these diabetic mice, whereas amounts of AKTphosphorylated, inactive InsP 3 Rs were reduced (Fig. 4b) . Correspondingly, knockdown of either calcineurin or InsP 3 Rs in db/db mice reduced CRE-Luc activity, gluconeogenic gene expression, and hepatic gluconeogenesis ( Fig. 4c and Supplementary Fig. 11c) .
Collectively, our results demonstrate that glucagon promotes CRTC2 dephosphorylation during fasting by triggering increases in cytoplasmic calcium that lead to calcineurin activation (Supplementary Fig. 12 ). The ability for glucagon to increase calcium signalling via the PKA-mediated phosphorylation of InsP 3 Rs demonstrates an important regulatory node for cross-talk between cAMP and calcium signalling pathways in liver and perhaps other insulin sensitive tissues. The partial inhibition of calcium entry by the PKA inhibitor H89 also points to additional regulatory inputs 12, 13 that may function with PKA to increase InsP 3 R activity in response to glucagon. CRTC2 has also been found to stimulate metabolic gene expression by upregulating the nuclear hormone receptor co-activator PGC-1a in liver 14, 15 and muscle 16 . On the basis of the well-recognized role of calcium signalling in PGC-1a-dependent transcription, InsP 3 Rs may also have an important function in this setting.
METHODS SUMMARY
Adenoviruses were delivered by tail vein injection 17 . Hepatic CRE-Luc activity was visualized using an IVIS Imaging system. Mice were imaged 3-5 days after injection of CRE-Luc adenovirus. Pyruvate tolerance testing was performed on mice fasted overnight and injected intraperitoneally with pyruvate (2 g kg
21
). Insp3r2 knockout mice have been described 10 . Cultured primary mouse hepatocytes were prepared as reported 18 . Cellular fractionation studies were conducted using primary mouse hepatocytes 18 . Calcium imaging experiments were performed using a CCD camera on primary hepatocytes loaded with fura-2 dye. Mass spectrometry studies were performed on CRTC2 immunoprecipitates prepared from HEK293T cells and on immunoprecipitates of phospho-PKA substrate antiserum prepared from primary hepatocytes exposed to glucagon. Anti-InsP 3 R1 (A302-158A) and InsP 3 R3 (A302-160A) antibodies were purchased from Bethyl Laboratories, anti-InsP 3 R2 (ab77838) antiserum was from Abcam, anti-calcineurin (610260) from BD Biosciences, anti-GRP78 (ADI-SPA-826-F) from Enzo Life Sciences, anti-phospho-PKA substrate (RRXS/T, 9624), anti-phospho-AKT substrate (RXXS/T, 9614) and CRTC2 (pS171, 2892) from Cell Signaling. Phospho (Ser 275) CRTC2 antibody was used as described 19 . For more details, see Supplementary Methods. LETTER RESEARCH
